Interní Med. 2005; 7(10): 430-432

Sex steroids and lipid spectrum in women

MUDr. Jana Vrbíková Ph.D
Endokrinologický ústav, Praha

Summary: Long-term risks of PCOS (diabetes mellitus type 2, ischemic heart disease and endometrial cancer) are now frequently discussed. Lipid levels were focused the most frequently. The common finding in PCOS is the decrease in HDL-cholesterol, increase in triglycerides and in LDL-cholesterol. We discuss the determinants of lipid spectrum in PCOS.

Keywords: Key words: androgens – cholesterol – triglycerides – polycystic ovary syndrome – metabolic syndrome – diabetes mellitus.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrbíková J. Sex steroids and lipid spectrum in women. Interní Med. 2005;7(10):430-432.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001; 285: 2486-2497. Go to original source... Go to PubMed...
    2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. Go to original source... Go to PubMed...
    3. Arlt, W. Management of the androgen-deficient woman. Growth Horm IGF Res 2003; 13 (Suppl A): S85-89. Go to original source... Go to PubMed...
    4. Bernini GP, Sgro M, Moretti A, Argenio GF, Barlascini CO, Cristofani R, Salvetti A. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999; 84: 2008-2012. Go to original source... Go to PubMed...
    5. Cibula D. Is insulin resistance an essential component of PCOS?: The influence of confounding factors. Hum Reprod 2004; 19: 757-759. Go to original source... Go to PubMed...
    6. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2699-2705. Go to original source... Go to PubMed...
    7. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 1509-1516. Go to original source... Go to PubMed...
    8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800. Go to original source...
    9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174. Go to original source... Go to PubMed...
    10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428. Go to original source... Go to PubMed...
    11. Elting MW, Korsen TJ, Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2001; 55: 767-776. Go to original source... Go to PubMed...
    12. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 2586-2593. Go to original source...
    13. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000; 85: 3251-3255. Go to original source...
    14. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684-1699. Go to original source... Go to PubMed...
    15. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312. Go to original source... Go to PubMed...
    16. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613. Go to original source... Go to PubMed...
    17. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 2005; 54: 1717-1725. Go to original source... Go to PubMed...
    18. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update 2003; 9: 359-372. Go to original source... Go to PubMed...
    19. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54: 447-453. Go to original source... Go to PubMed...
    20. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996; 44: 277-284. Go to original source... Go to PubMed...
    21. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51: 415-422. Go to original source... Go to PubMed...
    22. Van Beek AP, de Ruijter-Heijstek FC, Jansen H, Erkelens DW, de Bruin TW. Sex steroids and plasma lipoprotein levels in healthy women: The importance of androgens in the estrogen-deficient state. Metabolism 2004; 53: 187-192. Go to original source... Go to PubMed...
    23. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005. Go to original source...
    24. Vrbikova J, Hill M, Dvorakova K, Stanicka S, Vondra K, Starka L. Flutamide Suppresses Adrenal Steroidogenesis but Has No Effect on Insulin Resistance and Secretion and Lipid Levels in Overweight Women with Polycystic Ovary Syndrome. Gynecol Obstet Invest 2004; 58: 36-41. Go to original source... Go to PubMed...
    25. Weidemann W, Hanke H. Cardiovascular effects of androgens. Cardiovasc Drug Rev 2002; 20: 175-198. Go to original source... Go to PubMed...
    26. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002; 8: 231-241. Go to original source... Go to PubMed...
    27. Wild RA, Alaupovic P, Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol 1992; 166: 1191-1196; discussion 1196-1197. Go to original source... Go to PubMed...
    28. Wild RA, Bartholomew M, Applebaum-Bowden D, Demers LM, Hazzard W, Santen RJ. Evidence of heterogeneous mechanisms in lipoprotein lipid alterations in hyperandrogenic women. Am J Obstet Gynecol 1990; 163: 1998-2005. Go to original source... Go to PubMed...
    29. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951. Go to original source... Go to PubMed...
    30. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001; 76: 511-516. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.